The conversion of preferred stock and doubling of authorized shares create a large overhang of potential dilution. Monitor for any subsequent equity offerings or ATM programs that could pressure the stock. The expanded equity plans suggest management anticipates needing to issue shares for compensation and potentially for capital raises.
LXRX drugs
LXRX drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $1.63entry
- T+1 · 7mo ago −1.84%α −1.50% · $1.60
- T+5 · 6mo ago +3.07%α +0.72% · $1.68
- T+20 · 6mo ago +26.99%α +21.71% · $2.07
- T+60 · 4mo ago +43.56%α +40.49% · $2.34
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lexicon Pharmaceuticals filed an 8-K reporting the automatic conversion of all outstanding Series B Convertible Preferred Stock into 20.4M common shares, doubling authorized common shares to 900M, and stockholder approval of increased equity incentive plans. These actions significantly expand the company's share count and authorized capital, signaling potential future dilution but also providing flexibility for financing and employee retention.
Key Facts
- All 408,434.7 shares of Series B Convertible Preferred Stock converted into 20,421,735 shares of common stock at a ratio of 50:1.
- Authorized common stock increased from 450M to 900M shares via Seventh Amended and Restated Certificate of Incorporation.
- 2026 Equity Incentive Plan approved, increasing share reserve from 75M to 90M shares.
- 2026 Non-Employee Directors Equity Incentive Plan approved, increasing share reserve from 4M to 6M shares.
- All proposals at the annual meeting passed with overwhelming stockholder support (over 97% of votes cast).
Financial Impact
Immediate issuance of 20.4M new common shares upon conversion of preferred stock; authorized share count doubled to 900M, enabling significant future dilution potential.
Risk Factors
- Significant dilution from 20.4M new shares hitting the market upon conversion.
- Doubling of authorized shares signals potential for further equity raises, which could be dilutive.
- Increased equity incentive plan capacity may lead to ongoing dilution from employee stock awards.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001062822-26-000065 |
| Document: a2026equityincentiveplan.htm | 0001062822-26-000065 |
| Document: seventhamendedandrestate.htm | 0001062822-26-000065 |
| Document: a2026non-employeedirecto.htm | 0001062822-26-000065 |
| Document: 0001062822-26-000065-index-headers.html | 0001062822-26-000065 |
| Document: 0001062822-26-000065-index.html | 0001062822-26-000065 |
| Document: 0001062822-26-000065.txt | 0001062822-26-000065 |
Track record
16 reports on LXRX
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +27.52% at T+20 after the Sep 22, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.61 to $1.78 Now $1.75 +8.70% ▲ +10.56% +10.25% vs SPY
- Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $2.18 to $2.06 Now $1.75 +19.72% ▲ +5.50% +4.78% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 No price data
- Aug 6, 202614w ago Press Release Neutral 5/10 Entry $2.36 to $2.47 Now $1.75 −25.85% ▲ +4.66% +4.05% vs SPY
- Jun 12, 202622w ago Institutional Cluster Bearish 5/10 Entry $1.92 to $1.96 Now $1.75 +8.85% ▼ −2.08% −0.32% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.89 to $1.92 Now $1.75 −7.41% ▲ +1.59% +1.05% vs SPY
- May 6, 202627w ago 8-K Neutral 4/10 Entry $1.68 to $1.68 Now $1.75 +4.17% · 0.00% −0.83% vs SPY
- Apr 30, 202628w ago 8-K Bearish 6/10 Viewing Entry $1.63 to $1.60 Now $1.75 −7.36% ▲ +1.84% +1.50% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers